




RealRate

PHARMACEUTICAL 2020

Corbus Pharmaceuticals Holdings Inc. Rank 316 of 358





RealRate

PHARMACEUTICAL 2020

Corbus Pharmaceuticals Holdings Inc. Rank 316 of 358



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 168% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	38,155
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	34,888
Liabilities, Non-Current	8,097
Other Assets	5,904
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	5,651
Other Revenues	36,144
Property and Equipment	5,084
Research and Development	89,605
Selling, General and Administrative Expense	23,643

Output Variable	Value in 1000 USD
Assets	49,142
Liabilities	42,985
Expenses	113,248
Revenues	36,144
Stockholders Equity	6,158
Net Income	-71,454
Comprehensive Net Income	-71,454
Economic Capital Ratio	-132%